as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 28 Sep 2026
₹3,576.9
Change
-95.4 (-2.6%)
Open
₹3,672.3
Prev. Close
₹3,672.3
Day High
₹3,730.0
Day Low
₹3,556.8
Volume Analysis
Traded
29,057
Delivered
12,184
Delivery %
41.93%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (22.6%)
- •Strong operating margin (24.0%)
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (51.5%)
- •Strong 3-year revenue growth (26.1%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹3,858.86 | ₹3,794.43 | ₹3,685.66 | ₹3,621.23 | ₹3,512.46 | ₹3,448.03 | ₹3,339.26 |
| Fibonacci | ₹3,794.43 | ₹3,728.27 | ₹3,687.39 | ₹3,621.23 | ₹3,555.07 | ₹3,514.19 | ₹3,448.03 |
| Camarilla | ₹3,624.53 | ₹3,608.65 | ₹3,592.78 | ₹3,621.23 | ₹3,561.02 | ₹3,545.15 | ₹3,529.27 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-4.69%
1 Month
+7.92%
3 Months
+32.36%
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹683.63
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
22.24%
Net margin 14.62% × asset turnover 0.85x × equity multiplier 1.79x
Company Overview
Sector
Healthcare
Market Cap
₹3,824 Cr
P/E (TTM)
46.8
ROE
22.6%
Book Value
₹320.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Kwality Pharmaceuticals L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 64/100. The strongest factor is Financial Strength (95/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (22.6%); strong operating margin (24.0%). Strong 3-year EPS growth (51.5%).
TopFund Score — Fundamentals Quality
64/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 28 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- +Company has delivered good profit growth of 34.8% CAGR over last 5 years
- +Company has a good return on equity (ROE) track record: 3 Years ROE 18.1%
- +Company's median sales growth is 27.4% of last 10 years
- −Stock is trading at 11.5 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has high debtors of 203 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
AGM approved Swanith Kapoor as independent director and Aditya Arora’s 5-year reappointment from 30 Sept 2026.
Kwality Pharmaceuticals held its 43rd AGM on August 31, 2026, approving six resolutions including director reappointments.
Newspaper Publication of Unaudited Financial Results for the quarter ended June 30, 2026.
Newspaper Publication of Notice of 43rd Annual General Meeting.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 67 | 70 | 78 | 92 | 80 | 90 | 84 | 116 | 111 | 111 | 123 | 157 | 162 |
| Expenses + | 54 | 54 | 61 | 71 | 63 | 70 | 67 | 90 | 87 | 86 | 93 | 118 | 121 |
| Operating Profit | 14 | 15 | 17 | 21 | 17 | 20 | 18 | 26 | 24 | 25 | 30 | 39 | 41 |
| OPM % | 20.0% | 22.0% | 21.0% | 22.0% | 22.0% | 22.0% | 21.0% | 22.0% | 22.0% | 23.0% | 24.0% | 25.0% | 25.0% |
| Other Income + | 0 | 0 | 1 | -7 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
| Interest | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 3 |
| Depreciation | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 7 | 8 | 10 | 6 | 11 | 13 | 11 | 19 | 17 | 18 | 22 | 32 | 34 |
| Tax % | 25.0% | 24.0% | 21.0% | 29.0% | 25.0% | 33.0% | 25.0% | 24.0% | 30.0% | 23.0% | 28.0% | 20.0% | 25.0% |
| Net Profit + | 5 | 6 | 8 | 4 | 8 | 8 | 9 | 14 | 12 | 14 | 16 | 25 | 26 |
| EPS in Rs | 5 | 6 | 7 | 4 | 8 | 8 | 8 | 14 | 12 | 14 | 15 | 24 | 25 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 52 | 74 | 98 | 137 | 166 | 139 | 262 | 456 | 251 | 307 | 370 | 503 | 554 |
| Expenses + | 49 | 69 | 89 | 126 | 150 | 125 | 233 | 285 | 190 | 241 | 290 | 385 | 419 |
| Operating Profit | 3 | 5 | 9 | 12 | 16 | 14 | 29 | 172 | 61 | 66 | 80 | 118 | 135 |
| OPM % | 6.0% | 7.0% | 9.0% | 8.0% | 9.0% | 10.0% | 11.0% | 38.0% | 24.0% | 22.0% | 22.0% | 24.0% | 24.0% |
| Other Income + | 0 | 0 | 1 | 1 | 1 | 4 | 2 | 4 | -14 | -5 | 2 | 2 | 2 |
| Interest | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 7 | 10 | 10 | 11 | 11 |
| Depreciation | 1 | 2 | 3 | 3 | 3 | 4 | 6 | 11 | 15 | 20 | 18 | 20 | 20 |
| Profit before tax | 1 | 2 | 6 | 7 | 11 | 11 | 21 | 162 | 26 | 31 | 54 | 89 | 106 |
| Tax % | 41.0% | 48.0% | 42.0% | 39.0% | 31.0% | 25.0% | 30.0% | 26.0% | 25.0% | 24.0% | 26.0% | 25.0% | — |
| Net Profit + | 1 | 1 | 3 | 4 | 8 | 8 | 15 | 120 | 19 | 24 | 40 | 67 | 81 |
| EPS in Rs | 1 | 2 | 3 | 4 | 7 | 8 | 15 | 116 | 19 | 23 | 38 | 65 | 78 |
| Dividend Payout % | 0.0% | 0.0% | 9.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 15 | 17 | 20 | 19 | 27 | 36 | 51 | 171 | 190 | 214 | 254 | 321 |
| Borrowings + | 8 | 13 | 19 | 26 | 29 | 35 | 41 | 54 | 90 | 98 | 112 | 130 |
| Other Liabilities + | 10 | 17 | 26 | 40 | 39 | 52 | 64 | 105 | 70 | 72 | 71 | 130 |
| Total Liabilities | 37 | 51 | 71 | 96 | 105 | 133 | 166 | 341 | 361 | 394 | 447 | 592 |
| Fixed Assets + | 13 | 13 | 17 | 20 | 29 | 43 | 57 | 92 | 120 | 139 | 146 | 156 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 12 | 14 | 0 | 0 | 17 |
| Investments | 1 | 2 | 4 | 5 | 5 | 4 | 5 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 24 | 37 | 50 | 70 | 71 | 86 | 102 | 237 | 226 | 255 | 302 | 420 |
| Total Assets | 37 | 51 | 71 | 96 | 105 | 133 | 166 | 341 | 361 | 394 | 447 | 592 |
| Equity Capital | 4 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 1 | -3 | 4 | -1 | 14 | 6 | 27 | 61 | 41 | 43 | 53 | 17 |
| Cash from Investing Activity + | -1 | -2 | -7 | -6 | -12 | -18 | -23 | -63 | -48 | -26 | -29 | -35 |
| Cash from Financing Activity + | 1 | 6 | 5 | 5 | -2 | 12 | 1 | 6 | 1 | -17 | -14 | 7 |
| Net Cash Flow | 1 | 0 | 2 | -1 | 0 | 0 | 4 | 3 | -6 | -1 | 10 | -11 |
| CFO/OP | 51 | -30 | 76 | 21 | 108 | 62 | 115 | 59 | 78 | 67 | 85 | 32 |
| Free Cash Flow | 0 | -5 | -2 | -7 | 2 | -12 | 3 | 5 | -4 | 17 | 28 | -29 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 45.22% | 45.22% | 45.17% | 45.18% | 45.15% | 45.14% | 44.86% | 44.86% | 44.83% | 44.33% | 41.99% | 41.45% |
| Promoters | 54.76% | 54.76% | 54.82% | 54.82% | 54.82% | 54.82% | 54.82% | 54.82% | 54.82% | 54.82% | 54.87% | 54.86% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 2.79% | 3.13% |
| DII | 0.01% | 0.01% | 0.0% | 0.0% | 0.02% | 0.03% | 0.32% | 0.33% | 0.33% | 0.33% | 0.36% | 0.56% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Kwality Pharmaceuticals L (this stock) | 3,824 | 46.8 | 11.48 | 22.6% |
| Unichem Laboratories Ltd | 3,870 | 31.7 | 1.42 | 3.17% |
| Aarti Drugs Ltd. | 3,991 | 20.7 | 2.57 | 13.4% |
| Solara Active Pha Sci Ltd | 3,587 | 840.0 | 2.14 | -0.13% |
| Ind Swift Laboratories Lt | 3,489 | 53.6 | 2.52 | 3.87% |
| Gufic Biosciences Ltd. | 4,237 | 57.7 | 6.37 | 10.1% |
| Advanced Enzyme Tech Ltd | 3,278 | 20.8 | 2.01 | 10.2% |
Which Mutual Funds Hold Kwality Pharmaceuticals L?
Frequently Asked Questions about Kwality Pharmaceuticals L
Kwality Pharmaceuticals L (KPL) closed at ₹3,576.9 on NSE on 28 September 2026, down 95.4 (2.6%) from the previous close.
Kwality Pharmaceuticals L trades on the NSE (National Stock Exchange of India) under the symbol KPL.
Kwality Pharmaceuticals L has a trailing twelve-month P/E (price-to-earnings) ratio of 46.8.
Kwality Pharmaceuticals L has a dividend yield of 0.0%.
Kwality Pharmaceuticals L's 52-week high is ₹3,949.0 and its 52-week low is ₹829.0.
Kwality Pharmaceuticals L has a market capitalisation of ₹3,824 crore.
Kwality Pharmaceuticals L has a TopFund Quality Score of 64/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Kwality Pharmaceuticals L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.